Thermo Fisher Scientific (NYSE:TMO) Announces Earnings Results, Beats Estimates By $0.19 EPS

Thermo Fisher Scientific (NYSE:TMO) posted its quarterly earnings results on Thursday. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19, FiscalAI reports. The business had revenue of $11.01 billion during the quarter, compared to the consensus estimate of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same period last year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific updated its FY 2026 guidance to 24.640-25.120 EPS.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• Thermo Fisher raised full‑year guidance, now targeting $47.3B–$48.1B in revenue (6%–8% reported) and $24.64–$25.12 adjusted EPS (8%–10% growth), still assuming 3%–4% organic growth.
• Completed the ~\$9 billion acquisition of Clario, which added \$30M of revenue and \$0.01 of adjusted EPS in Q1 and is expected to contribute roughly \$900M of revenue and \$0.32 of EPS to 2026 guidance.
• Delivered a strong Q1 with \$11.01B revenue (+6%), adjusted operating income of \$2.4B (+6%) and adjusted EPS of \$5.44 (+6%), while returning capital via \$3B of buybacks and a 10% dividend increase.
• Headwinds persist from tariffs, FX and potential higher inflation (company cites a placeholder for inflation risk), and Analytical Instruments faced softness (organic -2%) with a 250 bps margin decline; China and academic/government end markets remain muted.
• Company highlighted continued innovation and commercial momentum—new product launches (e.g., Glacios 3 Cryo‑TEM, TSQ Certis, Gibco CTS Compleo), AI collaborations with Nvidia/OpenAI, and share gains in clinical research and bioproduction.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $469.27 on Friday. The company has a current ratio of 1.53, a quick ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock has a 50 day simple moving average of $499.11 and a 200-day simple moving average of $549.45. The company has a market cap of $174.39 billion, a PE ratio of 25.80, a P/E/G ratio of 2.41 and a beta of 0.97. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, April 15th. Stockholders of record on Friday, March 13th were given a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. This represents a $1.88 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat expectations — Thermo Fisher reported $5.44 adjusted EPS vs. ~$5.25 consensus and revenue of $11.01B (up ~6.2% y/y), showing the company still delivered above-street top- and bottom-line results. Reuters: Thermo Fisher posts quarterly results beat
• Positive Sentiment: Full-year guidance updated — Management set FY2026 EPS guidance of $24.64–$25.12 and raised its outlook, which supports longer-term earnings visibility even if organic growth is uneven. Yahoo: Thermo Fisher Raises 2026 Outlook
• Neutral Sentiment: Analyst reactions mixed but generally constructive — Several firms kept buy/outperform ratings while trimming targets (Stifel: $700->$600; Robert W. Baird: $653->$639), signaling continued confidence in the company’s fundamentals despite the pullback. Benzinga / The Fly: PT cuts
• Neutral Sentiment: Analyst voices emphasize long-term opportunity — Some analysts (e.g., TD Cowen, William Blair) reiterated Buy ratings, pointing to core growth drivers and structural demand (biopharma services, lab products) that support recovery later in the year. TipRanks: Analyst commentary
• Negative Sentiment: Market punished the stock on weak underlying growth and mixed segments — Despite the beat, investors focused on muted organic growth in the core business and uneven segment performance, which triggered a sharp intraday decline and premarket weakness. Yahoo: Why TMO Stock Is Nosediving
• Negative Sentiment: Broader sector & market pressure amplified the move — The mixed report pressured peers (e.g., 10x Genomics) and coincided with a softer tape for health care/tech stocks, adding to downward momentum. Yahoo: Peer impact (10x Genomics)

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $541.20, for a total transaction of $216,480.00. Following the sale, the executive vice president owned 20,752 shares of the company’s stock, valued at $11,230,982.40. The trade was a 1.89% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the sale, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Lavaca Capital LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $112,000. Wilkerson Advisory Group LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $48,000. Finally, Litman Gregory Wealth Management LLC purchased a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $121,000. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. TD Cowen decreased their price target on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday, January 30th. Wells Fargo & Company set a $683.00 target price on Thermo Fisher Scientific in a research note on Friday, January 30th. UBS Group restated a “neutral” rating and issued a $615.00 target price on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Robert W. Baird decreased their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research note on Friday. Finally, DZ Bank initiated coverage on Thermo Fisher Scientific in a research note on Friday, March 27th. They issued a “buy” rating and a $610.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $625.55.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.